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Abstract: (247 words)  
Background: Implications of different adiposity measures on cardiovascular disease 
aetiology remain unclear. In this paper we quantify and contrast causal associations of central 
adiposity (waist:hip ratio adjusted for BMI (WHRadjBMI)) and general adiposity (body mass 
index (BMI)) with cardiometabolic disease.  
Methods: 97 independent single nucleotide polymorphisms (SNPs) for BMI and 49 SNPs for 
WHRadjBMI were used to conduct Mendelian randomization analyses in 14 prospective 
studies supplemented with CHD data from CARDIoGRAMplusC4D (combined total 66,842 
cases), stroke from METASTROKE (12,389 ischaemic stroke cases), type 2 diabetes (T2D) 
from DIAGRAM (34,840 cases), and lipids from GLGC (213,500 participants) consortia. 
Primary outcomes were CHD, T2D, and major stroke subtypes; secondary analyses included 
18 cardiometabolic traits.  
Results: Each one standard deviation (SD) higher WHRadjBMI (1SD~0.08 units) associated 
with a 48% excess risk of CHD (odds ratio [OR] for CHD: 1.48; 95%CI: 1.28-1.71), similar 
to findings for BMI (1SD~4.6kg/m2; OR for CHD: 1.36; 95%CI: 1.22-1.52). Only 
WHRadjBMI increased risk of ischaemic stroke (OR 1.32; 95%CI 1.03-1.70). For T2D we 
find OR 1.82 (95%CI 1.38-2.42) per 1SD WHRadjBMI and OR 1.98 (95%CI 1.41-2.78) per 
1SD BMI. Both WHRadjBMI and BMI were associated with increased left ventricular 
hypertrophy, glycaemic traits, interleukin-6, and circulating lipids. WHRadjBMI was 
associated with carotid intima-media thickness (37%; 95%CI: 7%-74% per 1SD). 
Conclusions: Both general and central adiposity have causal effects on CHD and T2D. 
Central adiposity may have a stronger effect on stroke risk. Future estimates of adiposity 
burden on health should include measures of central and general adiposity.  
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Clinical Perspective: 
What is new: 
• This large-scale genetic analysis presents the most comprehensive causal assessment 
of adiposity with cardiometabolic diseases to date, including new data for ischaemic 
stroke from METASTROKE and novel cardiometabolic traits including ECG 
measures and CIMT.  
• We find that waist:hip ratio adjusted for BMI, a measure of body fat distribution that 
aims to be independent of general adiposity, is causally related to higher risks of 
coronary heart disease, ischaemic stroke and type 2 diabetes and a multitude of 
cardiometabolic traits.  
• Our findings also reinforce existing evidence on the causal relevance of general 
adiposity (BMI) to these diseases and provide more precise estimates. 
What are the clinical implications:  
• Both the amount of adiposity and its distribution play important roles in influencing 
multiple cardiometabolic traits and the development of cardiometabolic diseases.  
• Furthermore, our findings indicate that body fat distribution has multiple causal roles 
in disease that are independent of general adiposity.  
• This suggests that physicians should pay attention to measures of adiposity beyond 
BMI as measurement of such traits may identify patients at risk of cardiometabolic 
disease and provides opportunities to the scientific community to identify novel 
approaches to disease prevention.  
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Word count (4978)   
Introduction 
Observational studies have identified associations between adiposity and the risk of 
developing incident coronary heart disease (CHD), stroke and type 2 diabetes mellitus 
(T2D)1, 2. Many observational studies report consistent results with different measures of 
adiposity; for example the Emerging Risk Factors Collaboration found similar associations 
with both general adiposity measured via body mass index (BMI) and central adiposity 
measured via waist to hip ratio (WHR) for CHD and ischaemic stroke1. The association of 
different adiposity measures with T2D has also been found to be similar2. 
However, other studies have suggested that central adiposity, measured as either WHR or 
waist circumference (WC), may have stronger associations with cardiovascular disease. For 
example, INTERHEART found a stronger association for WHR with myocardial infarction 
(MI) than BMI, and the association of WHR with MI persisted after adjustment for BMI3. 
The Million Women Study found that WC increased CHD risk within BMI categories (and 
vice versa) again suggesting each is independently associated with CHD4.  Furthermore, 
INTERSTROKE found WHR to be more strongly associated with stroke risk than BMI5. 
While these studies have attempted to separate the independent effects of general and central 
adiposity, this remains challenging in observational studies due to the high degree of 
correlation between adiposity measures. Another problem is that adiposity measures may 
differ in their reproducibility; for example BMI is less affected by regression dilution bias – a 
bias to the null resulting from measurement error - than WHR 6. In addition, all measures of 
adiposity suffer from confounding due to underlying ill-health at low or sub-clinical levels, 
because many chronic conditions lead to weight loss7-9.  Consequently it is very difficult, if 
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not impossible, to quantify the true independent effects of different measures of adiposity in 
observational studies alone. 
Whilst Mendelian randomization (MR) studies minimise bias from traditional sources such as 
confounding, regression dilution bias and reverse causation, they may be susceptible to bias 
from pleiotropy (association of genetic variants with more than one variable). Pleiotropy can 
be vertical due to multiple downstream effects that follow the SNP effect on the exposure of 
interest, but this does not compromise MR assumptions. Alternatively, pleiotropy can be 
horizontal, whereby the SNP or instrument affects pathways other than those of the exposure 
of interest and could therefore invalidate the MR assumption that the SNP only affects the 
outcome through the exposure of interest, potentially leading to biased causal estimates. With 
multi-SNP instruments, there is a chance that pleiotropic effects might become balanced such 
that causal inference regarding the exposure is possible. In this study we perform MR 
analyses of BMI and WHR together with recently developed methods that are robust to 
horizontal pleiotropy under additional assumptions (Supplementary Figure 1).  We 
therefore employ MR-Egger regression to provide a test for unbalanced pleiotropy and a 
causal estimate of exposure on outcome in its presence10, 11.  In addition we use the weighted 
median estimator which can give valid estimates even in the presence of horizontal pleiotropy 
provided at least 50 per cent of the information in the analysis comes from variants that are 
valid instruments, and has the advantage of retaining greater precision in the estimates 
compared to MR-Egger12. 
This manuscript represents the most comprehensive assessment of the causal role of adiposity 
on CHD, stroke and T2D to date. It contrasts the causal effects of central adiposity (waist:hip 
ratio adjusted for BMI (WHRadjBMI) from general adiposity (BMI) on multiple 
cardiovascular outcomes: new CHD events from 14 prospective studies/ RCTs in addition to 
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data publicly available from the CARDIOGRAMplusC4D13 increasing CHD cases to 66,842, 
multiple stroke subtypes using data from METASTROKE14 and T2D from DIAGRAM15. We 
present the largest number of cardiometabolic traits ever examined in a MR analysis of 
adiposity  including lipids from the Global Lipids Genetic Consortium (GLGC; 213,500 
participants)16 and many novel intermediate disease end points, including electrocardiogram 
(ECG) measures of left ventricular hypertrophy, carotid intima media thickness (CIMT) as a 
measure of sub-clinical atherosclerosis, as well as markers of renal and lung disease.  We 
build distinct multi-SNP genetic instruments for each adiposity measure using the most 
comprehensive repertoire available from recent genome-wide association (GWA) studies17, 18,  
with 97 SNPs for BMI and 49 SNPs for WHRadjBMI, thereby more than doubling the 
phenotypic variance explained in some earlier MR studies19-23. 
 
Methods 
Study selection and inclusion of participants 
We include individual participant data from 10 studies in the University College London – 
London School of Hygiene and Tropical Medicine – Edinburgh - Bristol (UCLEB) 
consortium (see Supplementary Table 1 for study details). We include summary data from a 
further four studies (Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), Health and 
Retirement Study (HRS), Netherlands Epidemiology of Obesity (NEO) and Prospective 
Study of Pravastatin in the Elderly at Risk (PROSPER)), and summary data from four 
consortia (CARDIoGRAMplusC4D, METASTROKE, DIAGRAM, Global Lipids Genetics 
Consortium (GLGC)) (see Appendix). All participating studies received approval from local 
institutional review boards or ethics committees. 
Clinical Outcomes 
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Supplementary Table 2 provides details of CHD ascertainment and number of events by 
study. In UCLEB studies the primary outcome was combined prevalent or incident CHD 
defined as fatal or non-fatal myocardial infarction, or a coronary revascularisation procedure, 
but excluding angina. In the majority of studies events were validated (e.g. hospital episode 
statistics, clinical/laboratory measurements, review of primary care medical records). 
CARDIoGRAMplusC4D used standard criteria for defining cases of CAD and myocardial 
infarction with some studies including angiography-confirmed stenosis and stable or unstable 
angina13. METASTROKE define stroke as a typical clinical syndrome with radiological 
confirmation; subtyping was done with the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) classification system14. We include all ischaemic stroke, three sub-types (large-
vessel disease, small-vessel disease and cardioembolic stroke) and haemorrhagic stroke. T2D 
definitions follow DIAGRAM24.   
Cardiometabolic traits  
For analysis of individual participant data studies, data on sex, age, measured standing height, 
weight, waist circumference and hip circumference were used to derive BMI and 
WHRadjBMI traits. WHRadjBMI was calculated by generating the predicted residuals from 
the linear regression of WHR on BMI. Biomarkers included in analyses were grouped into 
the following categories; Lipids (triglycerides, HDL-C and LDL-C), inflammation (IL-6), 
lung function (ratio of FEV1 to FVC), metabolic (glucose, insulin and albumin), renal 
(creatinine, estimated glomerular filtration rate (EGFR), MDRD) and systolic blood pressure. 
The following electrocardiogram (ECG) measures of left ventricular hypertrophy were 
recorded:  QRS voltage sum, QRS voltage sum product, Cornell product and Sokolow-Lyon 
index as well as PR interval (see Supplementary Text 1 for definitions). Cardiometabolic 
traits that were not normally distributed were transformed to the natural logarithmic scale. 
Confidential draft – Please do not circulate 
 
 
9 
 
For comparability across biomarkers, measurements were z-score standardised. Self-reports 
of current smoking status (ever/ never) and alcohol consumption (drinker/ non-drinker) were 
considered to be potential confounders of adiposity-cardiovascular disease (CVD) 
associations.  
Genotyping 
Supplementary Table 1 details genotyping by study. Genotyping in all UCLEB studies was 
conducted with the Metabochip array (except a subset of ELSA study that used a GWAS 
array)25. The remaining studies used GWAS arrays (HRS, PROSPER) or Exome Chip 
(NEO). Individuals were excluded from the analyses on the basis of gender mismatch, 
excessive or minimal heterozygosity, relatedness or individual missingness (>3%). 
Individuals of non-European ancestry were removed to minimise confounding by population 
structure. SNPs with a low call rate or evidence of departure from Hardy–Weinberg 
equilibrium were excluded from analyses (see Supplementary Table 1 for thresholds 
employed in different studies).  
Statistical Analyses 
Observational Analyses 
In individual participant data studies adiposity (BMI or WHRadjBMI) was z-score 
standardised and linear or logistic regression models were fitted for each cardiometabolic trait 
or disease outcome.  Observational models were adjusted for age and sex. Fixed-effect meta-
analyses were employed to derive combined observational estimates across studies. We 
calculated I2 statistics to quantify heterogeneity between studies and derived P-values from 
Cochran’s Q test26.  
Genetic Analyses 
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SNP selection and construction of the genetic instruments  
Selection of SNPs for the genetic instruments was based on analyses from the Genetic 
Investigation of ANthropometric Traits (GIANT) consortium, which included 339,224 
individuals from 125 separate studies for BMI17 and 224,459 individuals from 101 studies for 
WHRadjBMI18.  These studies identified 97 independent SNPs for BMI and 49 independent 
SNPs for WHRadjBMI at GWAS significance. We found no overlap between the BMI SNPs 
and WHRadjBMI SNPs. In studies where the SNP identified by GIANT was not available in 
the Metabochip array, we used proxy SNPs in linkage disequilibrium (R2>0.8) with the 
specified SNP. Details of proxy SNPs used by platform (Metabochip/ GWAS) are given in 
Supplementary Tables 3 and 4. 
Genetic association analyses in individual participant data 
We performed a within study genetic association analysis with adiposity (standardised BMI 
and WHRadjBMI) as a continuous trait using an additive model. We used linear or logistic 
regression models to estimate the additive effect of each SNP on cardiometabolic traits and 
outcomes. We used logistic regression to test the association of each SNP with smoking and 
alcohol consumption as potential confounders of the adiposity-CVD association.  
Instrumental variable analyses in summary data 
We conducted three tests for the causal estimation of each adiposity measure on 
cardiometabolic outcomes: 1) Inverse-variance weighted method (IVW), 2) MR-Egger and 3) 
Weighted median. In the absence of horizontal pleiotropy, we would expect all three tests to 
give consistent results. All IV estimates in summary data were calculated using the mrrobust 
package (available from https://github.com/remlapmot/mrrobust) in Stata version 1427, 28. The 
proportion of variance in adiposity explained by the genetic instruments in summary data was 
calculated using the grs.summary function from the gtx package in R29, 30. A threshold of 
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statistical significance of P<0.025 (0.05/2=0.025) was used to reflect testing for two different 
adiposity traits (BMI and WHRadjBMI). 
1) IVW instrumental variable analyses 
To combine data across studies with summary level data we pooled the association of each 
SNP on risk of each CVD outcome/ cardiometabolic trait using fixed effects meta-analysis. 
To provide external weights for the SNP-adiposity associations, the effect of each SNP on 
adiposity (BMI; WHRadjBMI) in GIANT was pooled with that in all other contributing 
studies, excluding studies that had already contributed to GIANT (1958BC, EAS, HRS, 
NSHD, PROSPER,Whitehall II). To quantify heterogeneity in the SNP effects across studies 
we calculated I2 and derived P-values from Cochrane’s Q tests. All P-values were two-sided.  
Inverse-variance weighted meta-analysis (IVW) is used to provide a combined estimate of the 
causal estimates (SNP-outcome/ SNP-adiposity) from each SNP. IVW is equivalent to a two-
stage least squares or allele score analysis using individual-level data, and is hence referred to 
here as “conventional MR”31. However, it can lead to over-rejection of the null, particularly 
when there is heterogeneity between the causal estimates from different genetic variants. 
2) MR-Egger instrumental variable analyses  
To account for potential horizontal pleiotropy in the multi-SNP adiposity instruments, we re-
estimated the instrumental variable associations using MR-Egger regression10, 11. MR-Egger 
tests for presence of, and accounts for, unbalanced pleiotropy by introducing a parameter for 
this bias10. Specifically, linear regression of the instrument-outcome effects is performed on 
the instrument-exposure effects, with the slope representing the causal effect estimate and the 
intercept the net bias due to horizontal pleiotropy. An additional assumption is required that 
the individual SNP effects on the exposure are independent of their pleiotropic effects on the 
outcome (termed the ‘InSIDE assumption’)12.  
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3) Weighted median estimate instrumental variable analyses  
Finally, we applied a complementary approach termed the weighted median estimator which 
can give valid estimates even in the presence of horizontal pleiotropy provided at least half of 
the weighted variance is valid12.   
Power calculations 
Power to detect causal estimates was calculated based on the proportion of variance of the 
exposure explained by the instruments (R2), the total number of individuals in the analysis, 
and the number of cases and controls using the online tool 
http://cnsgenomics.com/shiny/mRnd/32. Power estimates are provided in (Supplementary 
Table 5) .  
 
 
Results 
Studies and participants 
Full descriptive details of the included studies are given in Supplementary Table 1.  Data 
from 14 prospective studies and randomised trials and four consortia were included with 
66,842 CHD cases (3,716 from UCLEB/ other non-consortia studies), 12,389 ischaemic 
stroke cases and 34,840 T2D cases. The number of individuals included in the analyses of 
cardiometabolic traits ranged from 6,625 to 213,556. The mean age in individual participant 
data  studies was 63.5 years, the mean BMI 27.4 kg/m2 (SD 4.6) and the mean WHR 0.89 
(SD 0.13) (Supplementary Tables 1 & 6). Distribution of binary traits by study are given in 
Supplementary Table 7. 
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Instrument validation  
We identified Metabochip proxies for 13 BMI SNPs and 7 WHRadjBMI SNPs; the median 
R2 was 0.965 & 0.913 respectively (Supplementary Tables 3 and 4). The proportion of 
variance (R2) of BMI explained by the BMI genetic instrument was 1.7% while the 
WHRadjBMI instrument explained 0.7% WHRadjBMI variance. The associations of 
individual SNPs with adiposity are shown in Supplementary Tables 8 and 9.  
 
Mendelian randomization analysis of adiposity with cardiometabolic traits  
Figure 1a/b presents estimates of associations between BMI and WHRadjBMI with 
cardiometabolic traits from IV analyses. Both genetically instrumented adiposity measures 
were found to be causally associated with increased insulin and triglycerides. In addition, 
BMI was causally associated with higher IL-6, with a directionally consistent result identified 
for WHRadjBMI. Both adiposity measures were also causally associated with decreased 
levels of HDL-C. However, only WHRadjBMI was associated with increased LDL-C, and 
the association with SBP was also stronger. BMI was inversely associated with albumin, 
while WHRadjBMI was not; but heterogeneity across studies was moderately high (I2=57%).  
There was evidence for a causal association with some of the ECG measures that index left 
ventricular hypertrophy with both adiposity measures associated with higher log Cornell 
Product; in addition BMI, but not WHRadjBMI associated with lower Sokolow-Lyon index. 
There was no suggestion for a causal association of either measure of adiposity and PR 
interval.  
Both WHRadjBMI and, to a weaker extent, BMI were causally associated with higher CIMT 
(31%, 95%CI: 7%, 56% and 16%, 95% CI: 1%, 32% higher per SD in WHRadjBMI and 
BMI, respectively). The association of WHRadjBMI with lung function (FEV1:FVC) was 
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0.12 units per SD (95%CI 0.01, 0.24), but the P-value of 0.04 does not meet the threshold 
which takes into account testing for multiple measures of adiposity.  There was no suggestion 
of a causal association of either adiposity measure with any of the measures of renal function.  
With MR-Egger regression there was no convincing evidence for directional pleiotropy in 
any of the associations of adiposity traits with continuous cardiometabolic traits 
(Supplementary Tables 10 and 11).  
Supplementary Figures 2a/b illustrate the consistency of observational and IV estimates for 
associations between adiposity and cardiometabolic traits (Supplementary Tables 12 and 
13). 
 
Mendelian randomization analysis of adiposity with cardiometabolic diseases  
Figures 2a-c show the association of each adiposity measure with CHD, ischaemic stroke and 
T2D from conventional IVW and weighted median MR analyses. MR-Egger estimates tended 
to be much more imprecise and are therefore presented separately in Supplementary Table 
14 to facilitate interpretation. 
  
Mendelian randomization analysis of adiposity with CHD  
The summary causal estimate per 1SD increment in BMI from conventional IVW MR was an 
OR for CHD of 1.36 (95%CI: 1.22, 1.52) (Figure 2a). MR-Egger regression suggested little 
evidence for unbalanced pleiotropy in the genetic instrument (intercept P-value=0.65), and 
both MR-Egger and weighted median estimates were consistent with the IVW estimate 
(Supplementary Figure 3a). Furthermore, MR estimates were consistent with observational 
estimates reported by the Emerging Risk Factors Collaboration (Figure 2a) 
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Similarly, we found an association between WHRadjBMI and CHD using conventional MR 
(OR 1.48, 95% CI 1.28, 1.71 per SD WHRadjBMI, Figure 2a and Supplementary Figure 
3b). The intercept for the MR-Egger test was 0.0134 (95%CI -0.0004,0.0278; P-value=0.06). 
The causal estimate from MR-Egger was imprecise (OR 0.89, 95% CI 0.52, 1.53), but the 
weighted median estimator (which retains more power than MR-Egger) provided a causal 
effect of 1.61 (95% CI 1.36, 1.90) which was consistent with the IVW result. 
 
Mendelian randomization analysis of adiposity with ischaemic stroke  
The causal OR for the association between BMI and ischaemic stroke was 1.09 (95%CI 0.93, 
1.28 per SD) (Figure 2b). Results from the MR-Egger analysis were compatible with no 
unbalanced pleiotropy (intercept P-value=0.73), and the weighted median estimator 
suggested no causal association (Supplementary Figure 3c). Estimates for association 
between BMI and stroke sub-types were imprecise and all included the null (Table 1). Thus, 
while all IV estimates include the Emerging Risk Factors Collaboration estimate, lack of 
precision hinders any clear causal evidence for an association between BMI and ischaemic 
stroke. 
Results do, however, provide some evidence for a causal association of WHRadjBMI with 
ischaemic stroke (OR 1.32, 95%CI 1.03, 1.70 per SD in WHRadjBMI) (Figure 2b). MR-
Egger regression was consistent with no unbalanced pleiotropy (intercept P-value=0.94), and 
the weighted median estimator was very close to the IVW (causal OR 1.34, 95%CI 0.97, 1.86 
per SD increase in WHRadjBMI) (Supplementary Figure 3d). Limited evidence was found 
for a causal association with stroke sub-types; all point estimates were consistently above one 
but precision was poor and 95% confidence intervals included the null (Table 1).   
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Mendelian randomization analysis of adiposity with T2D  
We found a causal OR for T2D of 1.98 (95%CI: 1.41, 2.78) per SD increase in BMI (Figure 
2c). Similar but stronger estimates were identified using MR-Egger (OR 3.70, 95% CI 1.63, 
8.41; P-value for pleiotropy=0.10) and weighted median estimator (OR 2.70, 95% CI 2.26, 
3.23). One BMI SNP (rs7903146) was an outlier (Supplementary Figure 3e) and is a marker 
for the TCF7L2 gene, a GWAS-identified locus for T2D33. We therefore repeated the T2D 
analysis excluding rs7903146 (Supplementary Table 15 yielding an IVW OR of 2.25 
(95%CI: 1.87, 2.71) per SD increase in BMI, with similar estimates from MR-Egger and 
weighted median estimators. 
Likewise, we found a causal relationship between WHRadjBMI and T2D (OR 1.82, 95% CI 
1.38, 2.42 per SD increase in WHRadjBMI, Figure 2c). MR-Egger did not provide evidence 
of unbalanced pleiotropy (P-value for pleiotropy=0.21), and the weighted median estimator 
result was consistent with the IVW (OR 1.64, 95% CI 1.25, 2.15) (Supplementary Figure 
3g). 
Multivariate Mendelian randomization 
We found some evidence for association of both adiposity instruments with smoking, but not 
with other major confounders (Supplementary Table 16). To account for this, sensitivity 
analyses were undertaken for each cardiometabolic disease using multivariate MR including 
the effect of each SNP used as instrument for BMI and WHRadjBMI on smoking. MR 
estimates were found to be robust to this adjustment (Supplementary Table 17), with 
generally consistent point estimates measured with greater imprecision reflecting the reduced 
power in these analyses. The multivariate MR (adjusted for smoking) for the causal 
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association of WHRadjBMI with ischaemic stroke was 1.27 (95% CI 0.84-1.93) broadly 
similar to 1.32 (95% CI 1.03-1.70) in the main IVW analysis, but with a wider confidence 
interval.We also included FEV1:FVC in these sensitivity analyses due to the likely 
association of this trait with smoking; again adjusted results were very similar to the main 
IVW results (Supplementary Table 17). 
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Discussion 
We conducted the most comprehensive MR analysis to date comparing the causal role of 
central and general adiposity in the development of multiple cardiovascular disease outcomes 
(CHD, multiple stroke sub-types and T2D). Owing to benefits of MR to minimize residual 
confounding by common lifestyle factors and underlying ill-health, we are able to quantify 
that one standard deviation increase in  genetically instrumented WHRadjBMI (~0.08 units) 
results in a ~50% increase in risk of CHD independent of BMI. This compares with the ~40% 
increase in risk of CHD we find per 1SD increase in genetically instrumented BMI (~4.6 
kg/m2) which is consistent with the observational effect derived from large prospective 
population cohorts including the Emerging Risk Factors Collaboration 1 (CHD HR 1.29 
[1.22-1.37] per 1SD) and the Prospective Studies Collaboration33    Thus, while observational 
studies such as the Emerging Risk Factors Collaboration  have found risk to be consistent 
across different measures of adiposity, our results suggest WHRadjBMI may have a stronger 
effect, although the greater imprecision in the MR estimates should also be considered.  
Similarly, while observational studies have found different measures of adiposity to have 
similar associations with risk of ischaemic stroke1, our result again suggest that WHRadjBMI 
may be more strongly associated (increased risk ~30% per 1SD). Recent findings from 
INTERSTROKE also suggest that WHR is a much stronger deleterious risk factor for 
ischaemic stroke5.  Our SBP results follow a similar pattern, with a much stronger association 
between central adiposity and SBP than general adiposity. This is also the first MR study to 
suggest potential causal association between central adiposity ischaemic stroke subtypes, and 
CIMT, a widely used surrogate measure of sub-clinical atherosclerosis.  
Previous adiposity MR studies used limited numbers of SNPs, (with weaker genetic 
instruments), fewer events and generally failed to find evidence for a causal association 
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between BMI and CHD19, 21.  However, one MR study using a 3-SNP allele score (FTO, 
MC4R, TMEM18) reported an OR of 1.52 (95% CI 1.12-2.05 for a 4 kg/m2 increase in BMI20 
, and most recently a MR study using a 32-SNP instrument for BMI found similar results for 
CHD to ours22. We do not however replicate the causal association between BMI and 
ischaemic stroke reported by the same study (hazard ratio per SD-increase of BMI 1.83; 95% 
CI 1.05-3.20)22, despite increasing the number of stroke cases tenfold. Furthermore, our 
results are in line with those for ischaemic stroke from the Emerging Risk Factors 
Collaboration and INTERSTROKE, including the apparently stronger association we find 
between central adiposity and stroke relative to general adiposity. Results for the causal 
association of WHRadjBMI with CHD and T2D are consistent with those from a recent MR 
analysis34.  
We present the largest number of cardiometabolic traits ever examined in a MR analysis of 
adiposity. The current findings are broadly consistent with earlier MR studies for glucose, 
triglycerides, HDL-C, SBP, and IL-6, providing further support for a detrimental impact of 
adiposity on the cardiovascular system19, 21, 23. However, we find no evidence for a causal 
association between BMI and LDL-C, consistent with some but not all earlier studies21, 23. A 
recent MR study found a causal effect of BMI and a wide range of lipid metabolites, 
including all LDL metabolites35, but was conducted in a younger, healthier population 
(average BMI ~24kg/m2) than is commonly included in MR studies (including the current 
one) and this could explain the discrepancy with our findings (as observational studies 
suggests the association of BMI and LDL-C plateaus beyond 27kg/m2) 33.  We also report 
novel positive causal associations of adiposity with the ECG measure log Cornell product (a 
measure of left ventricular hypertrophy; LVH). The negative association of BMI with 
Sokolow Lyon (an alternative measure of LVH) was unexpected and may represent a false 
positive. While both log Cornell product and Sokolow Lyon measure left ventricular 
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hypertrophy, log Cornell product is considered to be the better test for identifying LVH when 
measured against a gold standard36. 
This study demonstrates that central obesity (as quantified by WHRadjBMI) has a causal 
effect on CHD that is independent of BMI. This finding demonstrates the potential of MR 
approaches for investigating highly correlated adiposity measures that have proved 
challenging to disentangle in observational studies37In these analyses we find that 
WHRadjBMI has a more deleterious lipid profile than BMI, with detrimental associations of 
greater magnitude with triglycerides and HDL-C and association with LDL-C not found for 
BMI. The association of WHRadjBMI with CIMT is also of greater magnitude. Conversely, 
BMI appears to have a greater inflammatory effect than WHRadjBMI, and potentially a 
stronger effect on the ECG measures that index left ventricular hypertrophy as well as with 
glucose and T2D. The apparent lack of association of WHRadjBMI with glucose is 
surprising, but is potentially explained by a negative association of WHRadjBMI SNPs with 
BMI. Interestingly, a recent paper showed WHRadjBMI to associate with 2-hour fasting 
glucose suggesting that WHRadjBMI may have differential effects according to how glucose 
is measured; different mechanisms are likely to regulate fasting and 2-hour glucose34. In 
keeping with our findings, the discovery GWAS that identified 49 SNPs associated with 
WHRadjBMI18 found associations of the SNPs with concentrations of HDL-C, TG, LDL-C, 
adiponectin and fasting insulin. Furthermore, the study identified enrichment of WHRadjBMI 
SNPs for T2D and CHD.  
This study suggests that it is not only the volume of adiposity, but also its location, that is 
relevant for disease, lending weight to the emerging theory that the deposition of body fat 
plays important roles that are independent of total fat. For example, at a given BMI, there is 
considerable inter-individual variation in the amount of visceral fat, which shows associations 
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with disease38. Our results also suggest that efforts to quantify the effect of adiposity on 
burden of disease should include multiple measures of adiposity to avoid underestimating the 
true burden of adiposity on health39.As regards specific interventions that focus WHR more 
than BMI, there is observational evidence that physical activity can modify WHR 
independent of BMI40. Thus it may be possible to mitigate the effects of WHR through 
increased population-wide physical activity. In addition, our findings open potentially new 
avenues of investigation. For example, identifying these causal effects of WHRadjBMI can 
enable research to focus on the downstream consequences of this trait, and potentially 
identify traits (such as metabolites)35 that could mediate the relationship between 
WHRadjBMI and disease which may themselves be amenable to pharmacological 
modification. Such traits downstream of WHRadjBMI could be unique (and not shared with 
BMI) raising the possibility of novel opportunities for drug discovery and disease prevention.  
Strengths 
This study has many strengths. First, independent multi-SNP instruments comparing the 
effect of central and general adiposity on multiple CVD outcomes; second, the use of 
powerful genetic instruments for BMI and WHRadjBMI which explained up to twice the 
phenotypic variation compared with previous MR studies; third, large number of clinical 
events that provided ample power to detect the associations of adiposity with cardiometabolic 
diseases fourth, the use of methods to minimise the impact of unbalanced pleiotropy in the 
genetic instruments that may invalidate findings from conventional MR.  
In addition to this being the most comprehensive evaluation of adiposity-related traits with 
cardiovascular and metabolic risk factors and diseases, our analysis also facilitates their direct 
comparison, and therefore contrasts the effects of general adiposity with body fat distribution 
in the same datasets. This provides novel insights, demonstrating that WHRadjBMI is more 
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relevant to the development of subclinical atherosclerosis and stroke compared to BMI, 
whereas both BMI and WHRadjBMI are important for CHD and diabetes. 
 
Limitations 
Limitations include the potential pleiotropic effects of the multi-SNP instruments. However, 
results suggest little evidence for unbalanced pleiotropy. Re-estimates of the causal 
associations using MR-Egger regression were broadly consistent with our conventional MR 
analysis, albeit with a loss of precision and consequently a loss of power, while weighted 
median estimates (that retains more power than MR-Egger) proved remarkably similar to 
IVW.   
The InSIDE (Instrument Strength Independent of Direct Effect), which is untestable, assumes 
that the pleiotropic effects of the genetic variants are uncorrelated with the association of the 
genetic variants with the exposure. Violation of InSIDE would give rise to biased causal 
estimates from MR-Egger; however each MR approach has different strengths and 
assumptions, for example, violation of InSIDE does not affect the weighted median MR 
approach 12. This highlights the importance of using the three MR approaches (IVW, median 
and MR-Egger) in our study. General concordance of MR estimates derived from these 
approaches helps reinforce the conclusions that can be drawn.   We used a multi-SNP 
instrument for WHR that had already been adjusted for BMI as part of the GIANT GWAS18. 
Genetic instruments for phenotypes adjusted for heritable components may show association 
with the adjusted phenotype through collider bias41, which could violate the InSIDE 
assumption. Indeed, we found WHRadjBMI SNPs to be associated with BMI beyond what 
would be expected by chance (Supplementary Table 18). This could lead to biased results; 
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however in the current scenario the bias will tend to be towards the null (and underestimate 
the true effect) as the WHRadjBMI SNPs are associated negatively with BMI. 
We selected cardiometabolic traits a priori on the basis that previous studies have shown 
them to be observationally and genetically associated with BMI. Therefore, although we test 
multiple outcomes use of a conventional Bonferroni would over-penalize the interpretation. 
Future studies should look to include emerging CVD outcomes such as heart failure and atrial 
fibrillation, and consider additional potential confounders. In addition, more stroke cases 
should be added to improve precision in these analyses, in particular for multivariate MR 
analyses. 
Given that our MR analysis on CHD was largely based on summary data, we were unable 
undertake more detailed investigations of the linear relationship between BMI or 
WHRadjBMI and risk of CHD and/ or to explore the causal effects of very low levels of BMI 
or WHR on CHD42. These are important next steps to investigate, given the uncertainty 
regarding whether the U-shape association of BMI with disease reflects a true causal 
relationship, or whether it is an artefact from residual confounding and/or underlying ill-
health. The recent finding of a J-shaped (rather than U-shaped) association between BMI and 
mortality in healthy non-smokers reinforces the likely role of artefact this association43. 
Therefore, application of methods for non-linear MR could help to determine the true optimal 
level of BMI for health44. However, such analyses would require access to individual 
participant data in all studies.  
Finally, although we identify several downstream biological mechanisms by which general 
and central adiposity may mediate the effects on risk of CHD, these results should be 
considered as exploratory and further studies using adequate methodology for mediation 
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analysis should be conducted45, 46, including the analysis of finer resolution for cardio-
metabolic traits for example using NMR metabolomics. 
 
Conclusions 
Our study supports evidence for a causal role of both central and general adiposity in risk of 
CHD and T2D, and central adiposity in risk of ischaemic stroke. Furthermore, our results 
suggest that central adiposity may pose higher risk for stroke and CHD. Efforts to estimate 
the role of adiposity on cardiovascular disease should consider the potential independent 
effects of different measures of adiposity. 
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Figure 1a – Association of BMI with continuous biomarkers derived from Mendelian 
randomization analysis 
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Footnotes: 
Values represent mean difference per SD increase in BMI derived from conventional (IVW) Mendelian 
randomization analysis. 
Non-normally distributed variables were natural ln transformed; therefore mean differences displayed on the log 
scale may be anti-logged and interpreted as percentage differences in SD of trait per SD in BMI 
Log triglycerides from individual participant data studies only; GLGC triglycerides in Supplementary Table 10 
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Figure 1b – Association of WHRadjBMI with continuous biomarkers derived from 
Mendelian randomization analysis 
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Footnotes:  
Values represent mean difference per SD increase in WHRadjBMI derived from conventional (IVW) Mendelian 
randomization analysis. 
Non-normally distributed variables were natural log transformed; therefore mean differences displayed on the 
log scale may be anti-logged and interpreted as percentage difference in SD of trait per SD in WHRadjBMI 
Log triglycerides from individual participant data studies only; GLGC triglycerides in Supplementary Table 11 
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Figure 2a: Associations of adiposity with risk of CHD from observational and 
Mendelian randomization analyses  
 
 
 
Association between coronary heart disease and adiposity (BMI and WHR adjusted for BMI) comparing causal 
odds ratios (OR) per SD of adiposity trait derived from instrumental variable analysis and observational analysis 
from the Emerging Risk Factors Consortium hazard ratio (HR per SD of BMI or waist:hip adjusted for age, sex 
and smoking status). Causal estimates are derived from Mendelian randomization and include conventional 
(ratio) approach and weighted median (see Methods for further details). P(genetic pleiotropy) relates to the P-
value derived from the intercept of MR-Egger; a small P-value denotes presence of directional pleiotropy. 
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Figure 2b: Associations of adiposity with risk of ischaemic stroke from observational 
and Mendelian randomization analyses  
 
 
 
Association between ischaemic stroke and adiposity (BMI and WHR adjusted for BMI) comparing causal odds 
ratios (OR) per SD of adiposity trait derived from instrumental variable analysis and observational analysis from 
the Emerging Risk Factors Consortium (HR of ischaemic stroke per SD of BMI or waist:hip adjusted for age, 
sex and smoking status). Causal estimates are derived from Mendelian randomization and include conventional 
(ratio) approach and weighted median (see Methods for further details). P(genetic pleiotropy) relates to the P-
value derived from the intercept of MR-Egger; a small P-value denotes presence of directional pleiotropy. 
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Figure 2c: Associations of adiposity with risk of T2D from observational and Mendelian 
randomization analyses 
 
 
 
Association between T2D and adiposity (BMI and WHR adjusted for BMI) comparing causal odds ratios (OR) 
per SD of adiposity trait derived from instrumental variable analysis and observational analysis from Vazquez et 
al., 2007. Causal estimates are derived from Mendelian randomization and include conventional (ratio) approach 
and weighted median (see Methods for further details). P(genetic pleiotropy) relates to the P-value derived from 
the intercept of MR-Egger; a small P-value denotes presence of directional pleiotropy. 
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Table 1: Mendelian randomization estimates for the association of adiposity and stroke sub-types 
 
   IVW       Weighted median 
  OR LCI UCI I2 
  
P(Genetic 
pleiotropy) OR LCI UCI 
  
  
  
      
 BMI 
        All ischaemic stroke 1.09 (0.93, 1.28) 20% 0.734 0.98 (0.77, 1.25) 
Cardioembolic 1.18 (0.89, 1.55) 0% 0.507 1.40 (0.87, 2.24) 
Large vessel disease 1.14 (0.82, 1.59) 19% 0.625 1.12 (0.65, 1.91) 
Small vessel disease 0.93 (0.64, 1.35) 30% 0.270 1.15 (0.67, 1.97) 
Haemorrhagic stroke 1.51 (0.73, 3.13) 0% 0.435 1.28 (0.37, 4.40) 
         
         WHRadjBMI 
        All ischaemic stroke 1.32 (1.03, 1.70) 38% 0.936 1.34 (0.96, 1.87) 
Cardioembolic 1.24 (0.84, 1.83) 0% 0.588 1.32 (0.73, 2.38) 
Large vessel disease 1.37 (0.90, 2.09) 0% 0.470 0.87 (0.48, 1.58) 
Small vessel disease 1.57 (0.98, 2.51) 13% 0.861 1.71 (0.89, 3.29) 
Haemorrhagic stroke 1.89 (0.69, 5.18) 0% 0.430 1.73 (0.42, 7.06) 
                  
 
IVW: inverse variance weighted (also termed ‘conventional’ MR) and weighted median. P(genetic pleiotropy) relates to the P-value derived from the intercept of MR-Egger; a small P-value 
denotes presence of directional pleiotropy. 
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Appendix: Sources of summary data/ beta weights from genome-wide association consortia 
 
GIANT  
BMI and WHRadjBMI data were obtained from the GIANT consortium. The Genetic Investigation of 
ANthropometric Traits (GIANT) consortium is an international collaboration that seeks to identify genetic loci that 
modulate human body size and shape, including height and measures of obesity. The GIANT consortium is a 
collaboration between investigators from many different groups, institutions, countries, and studies, and the results 
represent their combined efforts. The primary approach has been meta-analysis of genome-wide association data and 
other large-scale genetic data sets. Anthropometric traits that have been studied by GIANT include body mass index 
(BMI), height, and traits related to waist circumference (such as waist-hip ratio adjusted for BMI, or WHRadjBMI). 
Thus far, the GIANT consortium has identified common genetic variants at hundreds of loci that are associated with 
anthropometric traits. 
https://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium 
 
CARDIoGRAMplusC4D 
CARDIoGRAMplusC4D (Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) 
plus The Coronary Artery Disease (C4D) Genetics) consortium represents a collaborative effort to combine data from 
multiple large scale genetic studies to identify risk loci for coronary artery disease and myocardial 
infarction.CARDIoGRAMplusC4D Metabochip is a two stage meta-analysis of Metabochip and GWAS studies of 
European and South Asian descent involving 63,746 cases and 130,681 controls. The CARDIoGRAM GWAS data 
was used as Stage 1 - data as published in: CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg 
C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Goldstein BA, Stirrups K, König 
IR,Cazier JB, Johansson A, Hall AS, Lee JY, Willer CJ, Chambers JC, Esko T, Folkersen L, Goel A, Grundberg E, 
Havulinna AS, Ho WK, Hopewell JC, Eriksson N, Kleber ME, Kristiansson K,Lundmark P, Lyytikäinen LP, Rafelt S, 
Shungin D, Strawbridge RJ, Thorleifsson G, Tikkanen E,Van Zuydam N, Voight BF, Waite LL, Zhang W, Ziegler A, 
Absher D, Altshuler D, Balmforth AJ,Barroso I, Braund PS, Burgdorf C, Claudi-Boehm S, Cox D, Dimitriou M, Do 
R, DIAGRAM Consortium, CARDIOGENICS Consortium, Doney AS, El Mokhtari N, Eriksson P, Fischer 
K,Fontanillas P, Franco-Cereceda A, Gigante B, Groop L, Gustafsson S, Hager J, Hallmans G,Han BG, Hunt SE, 
Kang HM, Illig T, Kessler T, Knowles JW, Kolovou G, Kuusisto J,Langenberg C, Langford C, Leander K, Lokki ML, 
Lundmark A, McCarthy MI, Meisinger C,Melander O, Mihailov E, Maouche S, Morris AD, Müller-Nurasyid M, 
MuTHER Consortium,Nikus K, Peden JF, Rayner NW, Rasheed A, Rosinger S, Rubin D, Rumpf MP, Schäfer 
A,Sivananthan M, Song C, Stewart AF, Tan ST, Thorgeirsson G, van der Schoot CE, Wagner PJ,Wellcome Trust 
Case Control Consortium, Wells GA, Wild PS, Yang TP, Amouyel P, Arveiler D,Basart H, Boehnke M, Boerwinkle 
E, Brambilla P, Cambien F, Cupples AL, de Faire U,Dehghan A, Diemert P, Epstein SE, Evans A, Ferrario MM, 
Ferrières J, Gauguier D, Go AS,Goodall AH, Gudnason V, Hazen SL, Holm H, Iribarren C, Jang Y, Kähönen M, Kee 
F, Kim HS,Klopp N, Koenig W, Kratzer W, Kuulasmaa K, Laakso M, Laaksonen R, Lee JY, Lind L,Ouwehand WH, 
Parish S, Park JE, Pedersen NL, Peters A, Quertermous T, Rader DJ,Salomaa V, Schadt E, Shah SH, Sinisalo J, Stark 
K, Stefansson K, Trégouët DA, Virtamo J,Wallentin L, Wareham N, Zimmermann ME, Nieminen MS, Hengstenberg 
C, Sandhu MS,Pastinen T, Syvänen AC, Hovingh GK, Dedoussis G, Franks PW, Lehtimäki T, Metspalu A,Zalloua 
PA, Siegbahn A, Schreiber S, Ripatti S, Blankenberg SS, Perola M, Clarke R, Boehm BO, O'Donnell C, Reilly MP, 
März W, Collins R, Kathiresan S, Hamsten A, Kooner JS,Thorsteinsdottir U, Danesh J, Palmer CN, Roberts R, 
Watkins H, Schunkert H and Samani NJ; Large-scale association analysis identifies new risk loci for coronary artery 
disease. Nat Genet 2013 45:25-33 
http://www.cardiogramplusc4d.org/ 
 
METASTROKE  
Ischaemic stroke data were obtained from the METASTROKE consortium. The METASTROKE consortium is 
supported by NINDS (NS017950). We thank all study participants, volunteers, and study personnel that made this 
consortium possible. The METASTROKE study consists of combined data from 15 GWAS of IS (12 389 cases vs 62 
004 controls). We used TOAST criteria17 to classify IS as large artery stroke (LAS) (2167 cases/49 159 controls from 
11 studies), cardioembolic stroke (CE) (2365 cases/ 56,140 controls from 13 studies), and small vessel disease (SVD) 
(1894 cases/51 976 controls from 12 studies). METASTROKE studies consisted of independently performed genome-
wide single nucleotide polymorphism (SNP) genotyping using standard technologies and imputation to HapMap 
release 21 or 22 CEU phased genotype18 or 1000 Genome 
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reference panels. Investigators contributed summary statistical data from association analyses using frequentist 
additive models for metaanalysis after application of appropriate quality control measures.  
 
DIAGRAM 
The DIAGRAM (DIAbetes Genetics Replication And Meta-analysis) consortium is a grouping of researchers with 
shared interests in performing large-scale studies to characterise the genetic basis of type 2 diabetes, and a principal 
focus on samples of European descent. The membership and scope of DIAGRAM has developed as the scale of 
collaboration in the field has increased. The initial instance of DIAGRAM (retrospectively termed "DIAGRAM v1") 
enabled the combination of T2D genome wide association (GWA) studies from the UK (WTCCC), DGI and FUSION 
groups: this meta-analysis, and consequent replication, resulted in identification of six novel signals influencing T2D 
risk (Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, 
Andersen G, Ardlie K, Boström KB, Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines PS, 
Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, 
Grallert H, Grarup N, Groves CJ, Guiducci C, Hansen T, Herder C, Hitman GA, Hughes TE, Isomaa B, Jackson AU, 
Jørgensen T, Kong A, Kubalanza K, Kuruvilla FG, Kuusisto J, Langenberg C, Lango H, Lauritzen T, Li Y, Lindgren 
CM, Lyssenko V, Marvelle AF, Meisinger C, Midthjell K, Mohlke KL, Morken MA, Morris AD, Narisu N, Nilsson P, 
Owen KR, Palmer CN, Payne F, Perry JR, Pettersen E, Platou C, Prokopenko I, Qi L, Qin L, Rayner NW, Rees M, 
Roix JJ, Sandbaek A, Shields B, Sjögren M, Steinthorsdottir V, Stringham HM, Swift AJ, Thorleifsson G, 
Thorsteinsdottir U, Timpson NJ, Tuomi T, Tuomilehto J, Walker M, Watanabe RM, Weedon MN, Willer CJ; 
Wellcome Trust Case Control Consortium, Illig T, Hveem K, Hu FB, Laakso M, Stefansson K, Pedersen O, Wareham 
NJ, Barroso I, Hattersley AT, Collins FS, Groop L, McCarthy MI, Boehnke M, Altshuler D., Nature Genetics 
2008;40(5):638-45). An incremental meta-analysis ("DIAGRAM v2" or "DIAGRAM+") adding GWA data from a 
further five studies (DGDG, KORA, Rotterdam, DeCODE, EUROSPAN for a total of 8,130 cases and 38,987 
controls) together with extensive replication involving 20 other cohorts, was central to identification of a further 17 
loci (Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, 
Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, Raychaudhuri S, McCarroll SA, 
Langenberg C, Hofmann OM, Dupuis J, Qi L, Segrè AV, van Hoek M, Navarro P, Ardlie K, Balkau B, Benediktsson 
R, Bennett AJ, Blagieva R, Boerwinkle E, Bonnycastle LL, Bengtsson Boström K, Bravenboer B, Bumpstead S, Burtt 
NP, Charpentier G, Chines PS, Cornelis M, Couper DJ, Crawford G, Doney AS, Elliott KS, Elliott AL, Erdos MR, 
Fox CS, Franklin CS, Ganser M, Gieger C, Grarup N, Green T, Griffin S, Groves CJ, Guiducci C, Hadjadj S, 
Hassanali N, Herder C, Isomaa B, Jackson AU, Johnson PR, Jørgensen T, Kao WH, Klopp N, Kong A, Kraft P, 
Kuusisto J, Lauritzen T, Li M, Lieverse A, Lindgren CM, Lyssenko V, Marre M, Meitinger T, Midthjell K, Morken 
MA, Narisu N, Nilsson P, Owen KR, Payne F, Perry JR, Petersen AK, Platou C, Proença C, Prokopenko I, Rathmann 
W, Rayner NW, Robertson NR, Rocheleau G, Roden M, Sampson MJ, Saxena R, Shields BM, Shrader P, Sigurdsson 
G, Sparsø T, Strassburger K, Stringham HM, Sun Q, Swift AJ, Thorand B, Tichet J, Tuomi T, van Dam RM, van 
Haeften TW, van Herpt T, van Vliet-Ostaptchouk JV, Walters GB, Weedon MN, Wijmenga C, Witteman J, Bergman 
RN, Cauchi S, Collins FS, Gloyn AL, Gyllensten U, Hansen T, Hide WA, Hitman GA, Hofman A, Hunter DJ, Hveem 
K, Laakso M, Mohlke KL, Morris AD, Palmer CN, Pramstaller PP, Rudan I, Sijbrands E, Stein LD, Tuomilehto J, 
Uitterlinden A, Walker M, Wareham NJ, Watanabe RM, Abecasis GR, Boehm BO, Campbell H, Daly MJ, Hattersley 
AT, Hu FB, Meigs JB, Pankow JS, Pedersen O, Wichmann HE, Barroso I, Florez JC, Frayling TM, Groop L, Sladek 
R, Thorsteinsdottir U, Wilson JF, Illig T, Froguel P, van Duijn CM, Stefansson K, Altshuler D, Boehnke M, 
McCarthy MI; MAGIC investigators; GIANT Consortium., Nature Genetics 2010;42(7):579-89). Whilst in the Voight 
(2010) paper, GWA data from the Framingham, ARIC and NHS studies was only used for in silico replication, the full 
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